Bone-healing pattern on critical-sized defects treated by rhPTH

María V. Jammal, Nina F. Pastorino, Carlos M. Abate, Shin Takagi, Hitoshi Nagatsuka, Liliana R. Missana

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Intermittent Recombinant Human Parathyroid Hormone (rhPTH 1-34) is an effective treatment for improving bone mass in patients with osteoporosis; however, its effects on bone regeneration are still unclear. The objective of this study was to evaluate the potential toxicity systemic rhPTH, as well as its ability to regenerate critical-sized defects (CZD) in bone. We used 43 female Wistar rats (body weight, 150 ± 50 g). Critical-sized bone defects in rat calvaria received vehicle alone (Control Group, CG) or daily rhPTH (20 ng/ Kg/day) by subcutaneous injection (Experimental Group, EG). We evaluated bone healing obtained at the 1st, 3rd, and 6th wks post-surgery by biochemical, soft x-ray, histological, and morphometric studies. In the EG, at the 1st and 3rd wks, many areas of focal osteoblast hyperplasia were found on parietal bone. At the 3rd wk, woven and/or lamellar bone, in an organized interconnected trabecular network, showed disrupted mineralization. At the 6th wk, looped bone was found to have formed patterns on parietal bone. New bone formed in the EG showed significant statistical differences (p = 0.023) at the 6th wk. Systemic rhPTH at the dose of 20 ng/Kg/ day was able to stimulate bone formation on rat CZD. Also, pre-existing and new bone showed non-proliferative forms of bone hyperostosis (increased non-neoplastic bone).

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalJournal of Hard Tissue Biology
Volume21
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Bone
Bone and Bones
Defects
Parietal Bone
Rats
Teriparatide
Hyperostosis
Bone Regeneration
Subcutaneous Injections
Osteoblasts
Osteogenesis
Skull
Osteoporosis
Hyperplasia
Wistar Rats
Body Weight
X-Rays
Surgery
Toxicity
Control Groups

Keywords

  • Bone hyperostosis
  • Bone regeneration
  • Critical-sized defect
  • Proliferative bone lesions
  • rhPTH

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biomaterials
  • Medicine (miscellaneous)
  • Orthopedics and Sports Medicine
  • Dentistry(all)

Cite this

Jammal, M. V., Pastorino, N. F., Abate, C. M., Takagi, S., Nagatsuka, H., & Missana, L. R. (2012). Bone-healing pattern on critical-sized defects treated by rhPTH. Journal of Hard Tissue Biology, 21(4), 443-450. https://doi.org/10.2485/jhtb.21.443

Bone-healing pattern on critical-sized defects treated by rhPTH. / Jammal, María V.; Pastorino, Nina F.; Abate, Carlos M.; Takagi, Shin; Nagatsuka, Hitoshi; Missana, Liliana R.

In: Journal of Hard Tissue Biology, Vol. 21, No. 4, 2012, p. 443-450.

Research output: Contribution to journalArticle

Jammal, MV, Pastorino, NF, Abate, CM, Takagi, S, Nagatsuka, H & Missana, LR 2012, 'Bone-healing pattern on critical-sized defects treated by rhPTH', Journal of Hard Tissue Biology, vol. 21, no. 4, pp. 443-450. https://doi.org/10.2485/jhtb.21.443
Jammal, María V. ; Pastorino, Nina F. ; Abate, Carlos M. ; Takagi, Shin ; Nagatsuka, Hitoshi ; Missana, Liliana R. / Bone-healing pattern on critical-sized defects treated by rhPTH. In: Journal of Hard Tissue Biology. 2012 ; Vol. 21, No. 4. pp. 443-450.
@article{a7bb53bb48d246ab95611dcbedea7896,
title = "Bone-healing pattern on critical-sized defects treated by rhPTH",
abstract = "Intermittent Recombinant Human Parathyroid Hormone (rhPTH 1-34) is an effective treatment for improving bone mass in patients with osteoporosis; however, its effects on bone regeneration are still unclear. The objective of this study was to evaluate the potential toxicity systemic rhPTH, as well as its ability to regenerate critical-sized defects (CZD) in bone. We used 43 female Wistar rats (body weight, 150 ± 50 g). Critical-sized bone defects in rat calvaria received vehicle alone (Control Group, CG) or daily rhPTH (20 ng/ Kg/day) by subcutaneous injection (Experimental Group, EG). We evaluated bone healing obtained at the 1st, 3rd, and 6th wks post-surgery by biochemical, soft x-ray, histological, and morphometric studies. In the EG, at the 1st and 3rd wks, many areas of focal osteoblast hyperplasia were found on parietal bone. At the 3rd wk, woven and/or lamellar bone, in an organized interconnected trabecular network, showed disrupted mineralization. At the 6th wk, looped bone was found to have formed patterns on parietal bone. New bone formed in the EG showed significant statistical differences (p = 0.023) at the 6th wk. Systemic rhPTH at the dose of 20 ng/Kg/ day was able to stimulate bone formation on rat CZD. Also, pre-existing and new bone showed non-proliferative forms of bone hyperostosis (increased non-neoplastic bone).",
keywords = "Bone hyperostosis, Bone regeneration, Critical-sized defect, Proliferative bone lesions, rhPTH",
author = "Jammal, {Mar{\'i}a V.} and Pastorino, {Nina F.} and Abate, {Carlos M.} and Shin Takagi and Hitoshi Nagatsuka and Missana, {Liliana R.}",
year = "2012",
doi = "10.2485/jhtb.21.443",
language = "English",
volume = "21",
pages = "443--450",
journal = "Journal of Hard Tissue Biology",
issn = "1341-7649",
publisher = "Society of Hard Tissue Regenerative Biology",
number = "4",

}

TY - JOUR

T1 - Bone-healing pattern on critical-sized defects treated by rhPTH

AU - Jammal, María V.

AU - Pastorino, Nina F.

AU - Abate, Carlos M.

AU - Takagi, Shin

AU - Nagatsuka, Hitoshi

AU - Missana, Liliana R.

PY - 2012

Y1 - 2012

N2 - Intermittent Recombinant Human Parathyroid Hormone (rhPTH 1-34) is an effective treatment for improving bone mass in patients with osteoporosis; however, its effects on bone regeneration are still unclear. The objective of this study was to evaluate the potential toxicity systemic rhPTH, as well as its ability to regenerate critical-sized defects (CZD) in bone. We used 43 female Wistar rats (body weight, 150 ± 50 g). Critical-sized bone defects in rat calvaria received vehicle alone (Control Group, CG) or daily rhPTH (20 ng/ Kg/day) by subcutaneous injection (Experimental Group, EG). We evaluated bone healing obtained at the 1st, 3rd, and 6th wks post-surgery by biochemical, soft x-ray, histological, and morphometric studies. In the EG, at the 1st and 3rd wks, many areas of focal osteoblast hyperplasia were found on parietal bone. At the 3rd wk, woven and/or lamellar bone, in an organized interconnected trabecular network, showed disrupted mineralization. At the 6th wk, looped bone was found to have formed patterns on parietal bone. New bone formed in the EG showed significant statistical differences (p = 0.023) at the 6th wk. Systemic rhPTH at the dose of 20 ng/Kg/ day was able to stimulate bone formation on rat CZD. Also, pre-existing and new bone showed non-proliferative forms of bone hyperostosis (increased non-neoplastic bone).

AB - Intermittent Recombinant Human Parathyroid Hormone (rhPTH 1-34) is an effective treatment for improving bone mass in patients with osteoporosis; however, its effects on bone regeneration are still unclear. The objective of this study was to evaluate the potential toxicity systemic rhPTH, as well as its ability to regenerate critical-sized defects (CZD) in bone. We used 43 female Wistar rats (body weight, 150 ± 50 g). Critical-sized bone defects in rat calvaria received vehicle alone (Control Group, CG) or daily rhPTH (20 ng/ Kg/day) by subcutaneous injection (Experimental Group, EG). We evaluated bone healing obtained at the 1st, 3rd, and 6th wks post-surgery by biochemical, soft x-ray, histological, and morphometric studies. In the EG, at the 1st and 3rd wks, many areas of focal osteoblast hyperplasia were found on parietal bone. At the 3rd wk, woven and/or lamellar bone, in an organized interconnected trabecular network, showed disrupted mineralization. At the 6th wk, looped bone was found to have formed patterns on parietal bone. New bone formed in the EG showed significant statistical differences (p = 0.023) at the 6th wk. Systemic rhPTH at the dose of 20 ng/Kg/ day was able to stimulate bone formation on rat CZD. Also, pre-existing and new bone showed non-proliferative forms of bone hyperostosis (increased non-neoplastic bone).

KW - Bone hyperostosis

KW - Bone regeneration

KW - Critical-sized defect

KW - Proliferative bone lesions

KW - rhPTH

UR - http://www.scopus.com/inward/record.url?scp=84870798968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870798968&partnerID=8YFLogxK

U2 - 10.2485/jhtb.21.443

DO - 10.2485/jhtb.21.443

M3 - Article

AN - SCOPUS:84870798968

VL - 21

SP - 443

EP - 450

JO - Journal of Hard Tissue Biology

JF - Journal of Hard Tissue Biology

SN - 1341-7649

IS - 4

ER -